enGene Therapeutics Inc. ENGN

BOSTON & MONTREAL, September 08, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates.

BOSTON & MONTREAL, September 01, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:

BOSTON & MONTREAL, August 04, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations dri

BOSTON & MONTREAL, July 16, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid ("detalimogene") if approved. Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk non-m

The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms. CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing

Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

BOSTON & MONTREAL, June 15, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company today announced its financial results for the second quarter ended April 30, 2026, and provided clinical and corporate updates.

Why enGene Therapeutics stock is suddenly on investors’ radar enGene Therapeutics (ENGN) is in the spotlight after updated interim data from its Phase 2 LEGEND trial in high risk, BCG unresponsive non muscle invasive bladder cancer, followed by sharp stock moves and fresh legal scrutiny. See our latest analysis for enGene Therapeutics. The latest LEGEND update has flipped sentiment, with the stock’s 1 day share price return of 80.56% decline feeding into a 7 day share price return of 76.34%...

In early May 2026, enGene Therapeutics reported interim Phase 2 LEGEND trial data for its bladder cancer candidate detalimogene voraplasmid, showing a 54% complete response rate but weaker durability than previously hoped, alongside mostly mild and manageable safety findings. The data release has triggered analyst downgrades and shareholder-rights investigations, highlighting how durability of response can be as critical as initial efficacy for late-stage biotech programs. With these...

Investing.com -- enGene Therapeutics was downgraded by five Wall Street firms after updated interim data from its pivotal LEGEND study of detalimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer showed an unexplained decline in efficacy.

Executives from enGene (NASDAQ:ENGN) provided an update on the company’s detalimogene program in non-muscle invasive bladder cancer (NMIBC), discussing recent protocol changes, regulatory interactions, and commercial planning as the study advances. Protocol amendments and response-rate improvement

enGene (NASDAQ:ENGN) CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-muscle invasive bladder cancer (NMIBC). Speaking at a Barclays event moderated by Senior Biotech Ana

enGene (NASDAQ:ENGN) Chief Executive Officer Ron Cooper outlined the company’s near-term regulatory and clinical plans for its lead program, detalimogene voraplasmid, during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. Cooper said the company expects to provide an